An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin

References

• Vippagunta SR, Wang Z, Hornung S, Krill SL. (2007). Factors affecting the formation of eutectic solid dispersions and their dissolution behavior. J Pharm Sci, 96:294–304.
   PubMed Web of Science ®Google Scholar
• Christian L, Jennifer D. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47–60.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT. (1999). Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci, 88:1058–1066.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Pinnamaneni S, Das NG, Das SK. (2002). Formulation approaches for orally administered poorly soluble drugs. Pharmazie, 57:291–300.
   PubMed Web of Science ®Google Scholar
• James K. (1986). Solubility and related properties. Vol 28. New York: Marcel Dekker Inc., 355–395.
   Google Scholar
• Chaumeil JC. (1998). Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol, 20:211–215.
   PubMed Web of Science ®Google Scholar
• Perrut M, Jung J, Leboeuf F. (2005). Enhancement of dissolution rate of poorly soluble active ingredients by supercritical fluid processes. Part II: Preparation of composite particles. Int J Pharm, 288:11–16.
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Rades T. (2001). Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol, 53:303–315.
   PubMed Web of Science ®Google Scholar
• Paradkar A, Ambike AA, Jadhav BK, Mahadik KR. (2004). Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm, 271:281–286.
   PubMed Web of Science ®Google Scholar
• Breitenbach J. (2002). Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm, 54:107–117.
   PubMed Web of Science ®Google Scholar
• Hamsaraj K, Vikram S, Rayasa R. (2006). Industrially Feasible Alternative Approaches in the Manufacture of Solid Dispersions: A Technical Report. AAPS Pharm Sci Tech, 7:87.
   PubMedGoogle Scholar
• Mallick S, Pattnaik S, Swain K, De PK, Saha A, Ghoshal G et al. (2008). Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. Eur J Pharm Biopharm, 68:346–351.
   PubMed Web of Science ®Google Scholar
• Descamps M, Willart JF, Dudognon E, Caron V. (2007). Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g). J Pharm Sci, 96:1398–1407.
   PubMed Web of Science ®Google Scholar
• Sethia S, Squillante E. (2003). Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst, 20:215–247.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. (2007). Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today, 12:1068–1075.
   PubMed Web of Science ®Google Scholar
• Loftsson T. (1998). Increasing the cyclodextrin complexation of drugs and drug biovailability through addition of water-soluble polymers. Pharmazie, 53:733–740.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Miro A, Quaglia F, Giannini L, Cappello B, La Rotonda M. (2006). Drug/cyclodextrin solid systems in designing hydrophilic matrices: A strategy to modulate drug delivery rate. Curr Drug Deliv, 3:373–378.
   PubMedGoogle Scholar
• Duchene D, Wouessidjewe D. (1990). Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm, 16:2487–2499.
   Web of Science ®Google Scholar
• Bekers O, Uijtendal EV, Beijnen JH, Bult A, Underberg WJ. (1991). Cyclodextrins in pharmaceutical field. Drug Dev Ind Pharm, 17:1503–1549.
   Web of Science ®Google Scholar
• El-Maradny HA, Mortada SA, Kamel OA, Hikal AH. (2008). Characterization of ternary complexes of meloxicam-HPbetaCD and PVP or L-arginine prepared by the spray-drying technique. Acta Pharm, 58:455–466.
   PubMed Web of Science ®Google Scholar
• Buchi N, Nalluri KP, Chowdary KV, Murthy R, Becket G, Crooks P. (2007). Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems. AAPS Pharm Sci Tech, 8:36.
   Google Scholar
• Mosher G, Thompson D. (2002) Complexation and cyclodextrins. In: Encyclopedia of Pharmaceutical Technology. 2nd edition. New York: Marcel Dekker Inc, 531–558.
   Google Scholar
• Kaneto U, Fumitoshi H, Tetsumi I. (1998). Cyclodextrin Drug Carrier Systems. Chem Rev, 98:2045–2076.
   PubMed Web of Science ®Google Scholar
• Noble S, Balfour JA. (1996). Meloxicam. Drugs, 51:424–30; discussion 431.
   PubMed Web of Science ®Google Scholar
• Türck D, Roth W, Busch U. (1996). A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol, 35(Suppl 1):13–16.
   PubMedGoogle Scholar
• Gates BJ, Nguyen TT, Setter SM, Davies NM. (2005). Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother, 6:2117–2140.
   PubMed Web of Science ®Google Scholar
• Kumar SG, Mishra DN. (2006). Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG. J Pharm Soc Jpn, 126:657–664.
   PubMed Web of Science ®Google Scholar
• Baboota S, Agarwal SP. (2002). Inclusion complexation of meloxicam with β-cyclodextrin. Ind J Pharm Sci, 64:408–411.
   Google Scholar
• Nath BS, Shiva Kumar HN. (2000). A 2(3) factorial studies on factors influencing meloxicam β-cyclodextrin complexation for better solubility. Ind J Pharm Sci, 62:129–132.
   Google Scholar
• Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. (2004). Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal, 35:75–86.
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Abdel-Salam HM, El-Sayad MA, Mekhel MM. (2004). Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS Pharmscitech, 5:e59.
   PubMed Web of Science ®Google Scholar
• Inamdar N, Bhise K, Memon S. (2008). Solubility enhancement and development of dispersible tablet of meloxicam. Asian J Pharm, 2:128–132.
   Google Scholar
• Yu L. (2001). Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev, 48:27–42.
   PubMed Web of Science ®Google Scholar
• Kaushal AM, Gupta P, Bansal AK. (2004). Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst, 21:133–193.
   PubMedGoogle Scholar
• Willart JF, Descamps M. (2008). Solid state amorphization of pharmaceuticals. Mol Pharm, 5:905–920.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. (1965). Advances in Analytical Chemistry and Instrumentation, Chapter 4. Phase Solubility Studies; Interscience: New York, pp., 117–212.
   Google Scholar
• ICH Q1C and Q1A: “Stability Testing of New Dosage Forms”. http://www.ikev.org/haber/stabilite/kitap/StabilityWorkshop/ICH.pdf
   Google Scholar